Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab

Rena Mei; Emily Pepe; David Y Oh; Katy K Tsai; Rishika Chugh; Michael G Kattah

doi:10.1093/ibd/izae259

Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab

Inflamm Bowel Dis. 2025 Apr 10;31(4):1182-1183. doi: 10.1093/ibd/izae259.

Authors

Rena Mei¹, Emily Pepe¹, David Y Oh¹, Katy K Tsai¹, Rishika Chugh¹, Michael G Kattah¹

Affiliation

¹ Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

No abstract available

Plain language summary

Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.